St. Louis encephalitis laboratory findings
|
St. Louis encephalitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
St. Louis encephalitis laboratory findings On the Web |
|
American Roentgen Ray Society Images of St. Louis encephalitis laboratory findings |
|
Risk calculators and risk factors for St. Louis encephalitis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Vishnu Vardhan Serla M.B.B.S. [2]
Overview
Laboratory Findings
In acute SLEV neuroinvasive disease cases, cerebrospinal fluid (CSF) examination shows a moderate (typically lymphocytic) pleocytosis. CSF protein is elevated in about a half to two-thirds of cases. Computed tomography (CT) brain scans are usually normal; electroencephalographic (EEG) results often show generalized slowing without focal activity.
SLEV is difficult to isolate from clinical samples and almost all isolates have come from brain tissue or CSF. In the absence of a sensitive and non-invasive virus detection method, serologic testing is the primary method for diagnosing SLEV infection. Combined with a consistent clinico-epidemiologic presentation, a rapid and accurate diagnosis of acute neuroinvasive SLEV disease can be made by the detection of SLEV-specific IgM antibody in serum or CSF. SLEV IgM tests are available commercially, in some state health department laboratories, and at CDC. A positive SLEV IgM test result should be confirmed by neutralizing antibody testing of acute- and convalescent-phase serum specimens at a state public health laboratory or CDC. To submit specimens for testing at CDC, contact your state health department. All SLEV disease cases should be reported to local public health authorities.